WCM Investment Management
growth, quality, international, active
Quarter Analysis
13F change notes for WCM Investment Management in 2026-03-31.
WCM's $44B international-growth book — TSMC top weight at 6.74% (53 quarters held, +100% unrealized, slight add). ASML 4.36%, AppLovin trimmed sharply but still at 4.25%. Two new positions: Medtronic 2.20% and aggressive Teva add +191% in shares to 2.64%. Top-3 weight came down 19.7% → 17.1%. Reads as WCM rotating from peak growth winners into more defensive quality (Medtronic, Teva).
-
★ HELD
TAIWAN SEMICONDUCTOR MANUFAC TSM
Top weight 6.74%, 53 quarters held at +100% unrealized — WCM's signature long-term TSMC position.
-
★ HELD
ASML HLDG NV ASML
40 quarters at +309% unrealized — the lithography anchor in the international-growth book.
-
★ HELD
APPLOVIN CORP APP
9 quarters at +296% unrealized; weight 6.79% → 4.25% on a small share trim — pure price-driven shrink as AppLovin pulled back.
-
★ HELD
AMAZON COM INC AMZN
53 quarters at +53% unrealized — the long-running US-anchor in the international-growth book.
-
▲ ADDED
TEVA PHARMACEUTICAL INDS LTD TEVA
Shares +191% to 2.64% weight — meaningful Teva conviction add; -5% unrealized.
-
+ NEW
MEDTRONIC PLC MDT
New 2.20% — defensive med-devices entering the book.